Servier completes takeover of Day One Biopharmaceuticals stock

Published on 10/02/2026 at 01:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Servier paid USD 21.50 per share on April 23, 2026. Day One Biopharmaceuticals stock became private in a USD 2.5 billion deal.

DAWN, US23954D1090, Illustration mit AI erstellt.

Day One Biopharmaceuticals (US23954D1090) became a wholly owned Servier subsidiary after a cash transaction valued at approximately USD 2.5 billion on April 23, 2026. According to StockTitan, Servier paid USD 21.50 for each Day One share and the deal ended the company's Nasdaq listing.

Servier sets the final equity value

The transaction's USD 21.50 cash consideration provides the clearest market reference for the former DAWN security. The offer expired on April 22, 2026, after 88,180,910 shares, representing 85.34 percent of shares then outstanding, were validly tendered, according to StockTitan.

The merger converted the remaining shares into the same cash right and transferred Day One into Servier ownership. Former directors and officers were replaced by Servier designees, while the equity incentive plans and employee stock purchase plan were canceled, the filing summary states.

Revenue reached USD 158.2 million

Day One entered the transaction after fiscal 2025 total revenue reached USD 158.2 million, compared with USD 131.2 million in fiscal 2024. The two-year comparison shows a USD 27.0 million increase, while the company still reported a fiscal 2025 net loss of USD 107.3 million, according to StockTitan.

The same company update listed 2026 U.S. net product revenue guidance of USD 225 million to USD 250 million for OJEMDA. That range positioned the commercial product as the central operating asset before the takeover, alongside pipeline programs including Emi-Le and DAY301.

DAWN leaves the Nasdaq record

MarketBeat identifies Day One as a healthcare biotechnology company formerly traded on Nasdaq under the symbol DAWN. The company describes its strategy as advancing targeted medicines for childhood and adult diseases, with OJEMDA as its leading commercial therapy.

For former public-market investors, the key transition is from daily stock valuation to ownership of the acquired operating business. The April 23, 2026 cash settlement, the USD 2.5 billion equity value and the fiscal 2025 revenue base define the financial record carried forward under Servier ownership.